Community-wide infectious disease and immune response tracking using wastewater proteomics

14 March 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in a global pandemic, leading to the need for effective surveillance and monitoring strategies. The identification of SARS-CoV-2 peptides and acute phase response proteins in wastewater using mass spectrometry (MS) and the wastewater-based epidemiology concept is a promising tool for the surveillance of infectious diseases. MS provides high specificity and sensitivity for the identification of SARS-CoV-2 peptides in wastewater, allowing for early detection of outbreaks and real-time monitoring of disease trends. The quantification of acute phase response proteins in wastewater provides valuable information on the dynamics of the immune response to SARS-CoV-2, including the kinetics of cytokine production and the levels of acute phase response proteins in wastewater samples. In this study, we developed the first comprehensive mass spectrometry-based framework enabling simultanous tracking of infectious disease spread and community response to facilitate rapid disease management at the community level. SARS-CoV-2 was used as a test pathogen and C-reactive protein (CRP) as an acute phase response protein. The high specificity and sensitivity of MS, combined with the ability to provide a population-level perspective on the spread of the virus, make it a valuable tool for the surveillance of SARS-CoV-2. To our knowledge, this is the first report to use LCMS/MS to measure SARS-CoV-2 and its corresponding acute phase responsive human CRP protein in wastewater.


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.